



NUBEQA (darolutamide)

Instructions

Please complete Part A and have your physician complete Part B. This form may not apply to your specific plan. Before completing the Prior Authorization form, check that this medication is on your plan's drug coverage list. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. If you've already purchased the drug, please attach your original receipts along with a regular extended health care claim form.

Part A - Patient Patient Information

r acione imorriacio	711				
First Name:			Last Name:		
Insurance Carrier Name/Number:					
Group Number:			Client ID:		
Date of Birth (YYYY/MM/DD):			Relationship: Employee Spouse Dependent		
Language: English French			Gender: Male Female		
Address:					
City:		Province:		Postal Code:	
Email address:					
Telephone (home):		Telephone (cell):		Telephone (work):	
Please check any box that applies to the patient: The patient is an over-age student dependent (i.e. attending University or College full-time). A copy of the enrolment document from the educational institution confirming full-time status is enclosed. The patient is a spouse or a dependent over age 18. The patient has signed the authorization section below that allows Sun Life to obtain the additional medical information pertaining to this request.					
Coordination of benefits					
Provincial Coverage	You applied for a drug that may be covered under a provincial plan. To find out if you qualify for coverage, speak to your doctor and apply to the province. Show the provincial response letter to your pharmacist when you receive it.				
Primary Coverage	Has the patient applied for reimbursement under a primary plan? Yes No N/A What is the coverage decision of the drug? Approved Denied *Attach decision letter*				





NUBEQA (darolutamide)

Authorization

The answers on this form are true. I allow Sun Life to collect, use and disclose my personal information for three reasons. These reasons are plan administration, underwriting coverage and assessing claims. Sun Life may share (meaning collect and disclose) information with healthcare providers, hospitals, clinics, pharmacies, government programs, patient assistance programs, and any other organization with relevant information about me. Sun Life may also share information with insurers or reinsurers, and agents and service providers of Sun Life and the above parties. Sun Life will share my information only when necessary. My consent applies while this plan is in effect.

I agree that a photocopy or electronic version of this authorization is as valid as the original.

Plan Member Signature	Date
Patient Signature (if over 18 years of age)	- Date





NUBEQA (darolutamide)

Part B - Prescriber

Please see instructions on page 1 and complete all sections below. <u>Incomplete forms may result in automatic denial</u>. Please do **not** provide genetic test information or results.

NUBEQA (darolutamide)		New re	☐ New request ☐ Renewal request*		
DIN(s)	Dose	Administration (ex: oral, IV, etc)	Frequency	Duration	
Site of drug administrat	ion:				
	sician's office/Private	Clinic Private Clinic (within Hos	pital - no public or gov	vernment funding)	
		_	P		
Hospital (inpatient)	Hospital (ou	tpatient)			
Name of the hospital or	private clinic:				
Address:					
City:		Province:	Postal code:		
orty.		Trovince.	1 ostal code.		
* Please submit proof	f of prior coverage if a	available			
* Please submit proof	f of prior coverage if a	available			
·		available			
SECTION 2 – ELIGIB	ILITY CRITERIA				
SECTION 2 – ELIGIB					
ECTION 2 - ELIGIB 1. Please indicate if t	ILITY CRITERIA he patient satisfies the	he below criteria:			
1. Please indicate if t	ILITY CRITERIA he patient satisfies the contraction of the contraction	he below criteria:	nCRPC) in an adult, Al	ND	
1. Please indicate if t Prostate Cancer – Non For the treatm The patient is	ILITY CRITERIA he patient satisfies the considered to be at his considered to	he below criteria: on-Resistant			
1. Please indicate if to Prostate Cancer – Non- For the treatm The patient is (PSADT) of 10	ILITY CRITERIA he patient satisfies the considered to be at he months or less, AND	he below criteria: on-Resistant c castration-resistant prostate cancer (no	Prostate Specific Ant		
Prostate Cancer - Non- For the treatm (PSADT) of 10 The patient ha	ILITY CRITERIA he patient satisfies the considered to be at he months or less, AND is experienced disease.	he below criteria: on-Resistant c castration-resistant prostate cancer (now ligh risk of developing metastases with a see progression despite bilateral orchiectors	Prostate Specific Antomy, OR	igen Doubling Time	
Prostate Cancer - Non- For the treatm The patient is (PSADT) of 10 The patient ha The patient ha	ILITY CRITERIA he patient satisfies the considered to be at he months or less, AND is experienced disease sexperienced disease.	he below criteria: on-Resistant c castration-resistant prostate cancer (not igh risk of developing metastases with a see progression despite bilateral orchiectors progression despite androgen deprivation.	Prostate Specific Antomy, OR tion therapy (ADT), AN	igen Doubling Time D	
Prostate Cancer - Non- For the treatm The patient is (PSADT) of 10 The patient ha The patient ha	ILITY CRITERIA he patient satisfies the Metastatic, Castratic ent of non-metastatic considered to be at his months or less, AND is experienced disease a experienced disease e used in combinatio	he below criteria: on-Resistant c castration-resistant prostate cancer (now ligh risk of developing metastases with a see progression despite bilateral orchiectors	Prostate Specific Antomy, OR tion therapy (ADT), AN	igen Doubling Time D	
Prostate Cancer - Non- For the treatm The patient is (PSADT) of 10 The patient ha The patient ha NUBEQA will be	ILITY CRITERIA he patient satisfies the Metastatic, Castratic ent of non-metastatic considered to be at his months or less, AND is experienced disease a experienced disease e used in combinatio	he below criteria: on-Resistant c castration-resistant prostate cancer (not igh risk of developing metastases with a see progression despite bilateral orchiectors progression despite androgen deprivation.	Prostate Specific Antomy, OR tion therapy (ADT), AN	igen Doubling Time D	
1. Please indicate if to Prostate Cancer – Non- For the treatm The patient is (PSADT) of 10 The patient ha The patient ha NUBEQA will be had a bilateral	ILITY CRITERIA he patient satisfies the patient satisfies the patient satisfies the patient of non-metastation considered to be at his months or less, AND is experienced disease as experienced disease is experienced disease in combination or or chiectomy	he below criteria: on-Resistant c castration-resistant prostate cancer (noting the risk of developing metastases with a see progression despite bilateral orchiectors are progression despite androgen deprivation with a gonadotropin-releasing hormone	Prostate Specific Antomy, OR tion therapy (ADT), AN	igen Doubling Time D	
Prostate Cancer – Non- The patient is (PSADT) of 10 The patient ha NUBEQA will be had a bilateral	ILITY CRITERIA he patient satisfies the Metastatic, Castration ent of non-metastation considered to be at his months or less, AND is experienced disease as experienced disease e used in combination orchiectomy	he below criteria: on-Resistant c castration-resistant prostate cancer (noting the risk of developing metastases with a see progression despite bilateral orchiectors are progression despite androgen deprivation with a gonadotropin-releasing hormone	Prostate Specific Antomy, OR tion therapy (ADT), ANe (GnRH) analog unles	igen Doubling Time D	
Prostate Cancer – Non- The patient is (PSADT) of 10 The patient ha The patient ha NUBEQA will be had a bilateral Prostate Cancer – Meta	ILITY CRITERIA he patient satisfies the Metastatic, Castration ent of non-metastation considered to be at his months or less, AND is experienced disease as experienced disease e used in combination orchiectomy	he below criteria: on-Resistant c castration-resistant prostate cancer (not light risk of developing metastases with a see progression despite bilateral orchiectors progression despite androgen deprivation with a gonadotropin-releasing hormone ensitive	Prostate Specific Antomy, OR tion therapy (ADT), ANe (GnRH) analog unles	igen Doubling Time D	
1. Please indicate if to Prostate Cancer – Non- For the treatm The patient is (PSADT) of 10 The patient ha NUBEQA will be had a bilateral Prostate Cancer – Meta For the treatm For the treatm The patient ha	ILITY CRITERIA he patient satisfies the patient satisfies the patient satisfies the patient of non-metastation considered to be at high months or less, AND is experienced disease as experienced disease in combination or chiectomy astatic, Castration-See ent of metastatic cases in a bilateral or chiectory	he below criteria: on-Resistant c castration-resistant prostate cancer (not light risk of developing metastases with a see progression despite bilateral orchiectors progression despite androgen deprivation with a gonadotropin-releasing hormone ensitive	Prostate Specific Antomy, OR tion therapy (ADT), ANde (GnRH) analog unless C) in an adult, AND	igen Doubling Time D	





NUBEQA (darolutamide)

OR None of the above criteria applies.				
Relevant additional information:				
SECTION 3 - PRESCRIBER INFORMATION				
Physician's Name:				
Address:				
Tel:	Fax:			
License No.:	Specialty:			
Physician Signature:	Date:			

SECTION 4 - RESPECTING YOUR PRIVACY

Our Purpose is to help our Clients achieve lifetime financial security and live healthier lives. We collect, use and disclose your personal information to: develop and deliver the right products and services; enhance your experience and manage our business operations; perform underwriting, administration and claims adjudication; protect against fraud, errors or misrepresentations; tell you about other products and services; and meet legal and security obligations. We collect it directly from you, when you use our products and services, and from other sources. We keep your information confidential and only as long as needed. People who may access it include our employees, distribution partners such as advisors, service providers, reinsurers, or anyone else you authorize. At times, unless we're prohibited, they may be outside your jurisdiction and your information may be subject to local laws. You can always ask for your information and to correct it if needed. In most cases, you have a right to withdraw your consent, but we may not be able to provide the requested product or service. Read our Global Privacy Statement and local policy at www.sunlife.ca/privacy or call us for a copy.

Questions? Please visit www.sunlife.ca or call toll-free 1-800-361-6212 Monday - Friday, 8 a.m. - 8 p.m. ET





NUBEQA (darolutamide)

SECTION 5 - CONTACT US

	You can submit all pages of this form through the mysunlife mobile app or mysunlife.ca. Please use 'prior auth' as the
Ш	reference number.

OR

Please fax or mail the completed form to Sun Life Assurance Company of Canada ®

FAX: 1-855-342-9915 Mail:

Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 11658 STN CV Montreal, QC H3C 6C1 Sun Life Assurance Company of

Canada

Attention: Claims Dept.
PO Box 2010 STN Waterloo
Waterloo, ON N2J 0A6